Related Experiment Video For Pancreatic cancer
Updated: Nov 10, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26
Egle Zalyte1, Veronika Dedonyte2, Benediktas Kurlinkus3
1Proteomics Centre, Institute of Biochemistry, Vilnius University Life Sciences Centre, Vilnius, Lithuania; egle.zalyte@gf.vu.lt.
Background/Aim:
Pancreatic ductal adenocarcinoma is one of the deadliest forms of human cancer. Since only a vast panel of cell lines can fully recapitulate disease heterogeneity, our aim was to establish a new pancreatic cancer cell line.
Materials And Methods:
Newly established pancreatic ductal adenocarcinoma cell line Capan-26 was characterized by assessing growth rate, tumor and stem cell marker expression, colony forming efficiency, mutations of KRAS and TP53 genes, karyotype and sensitivity to drug treatment.
Results:
Cell doubling time was 74 h. We detected CA19-9, CEACAM6, CD44, OCT4 and ZEB1 expression in Capan-26 cell line. Cells formed colonies in soft agar, have a deletion of KRAS exon 3 and a point mutation V172F in TP53 exon 5. They are a mixed aneuploid/polyploid population with high sensitivity to gemcitabine.
Conclusion:
Capan-26 is a unique cell line that may be used to study the mechanism of pancreatic cancer.
